Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03689855
Title Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Washington University School of Medicine
Indications

lung non-small cell carcinoma

Therapies

Atezolizumab + Ramucirumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Washington University School of Medicine Saint Louis Missouri 63110 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field